Target Validation Information
TTD ID	T14065
Target Name	Integrin beta-7 (ITGB7)
Type of Target	Successful
Drug Potency against Target	TR-14035	Drug Info	IC50 = 0.75 nM	[1]
Action against Disease Model	Vedolizmab	Drug Info	Vedoliz uMab inhibited high-affinity adhesion of alpha 4 beta 7-espressing RPMI8866 cells (Mn2+-activated) to MAdCAM-1 with a mean IC50 value of 0.058 ???0.024 ug/ml (0.39 ???0.16 nM; n = 6)	[2]
References
REF 1	The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2709-13.
REF 2	The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.